FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average burden										
l	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  DONENBERG PHILIP B  (Last) (First) (Middle)  111 BARCLAY BLVD  (Street)  LINCOLNSHIRE IL 60069					2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [ BPAX ]  3. Date of Earliest Transaction (Month/Day/Year) 01/25/2012  4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ir	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  Sr VP of Finance, CFO, Secy  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person				
(City) (State) (Zip)												Form filed by More than One Reporting Person				ing	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Tra Date (Mont					action 2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		rities Acquired (A) or d Of (D) (Instr. 3, 4 and		Securitie Beneficia Owned F Reported Transacti	Reported Transaction(s)		Direct I Indirect I str. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)		
Common Stock						+		1			(D) Price		+	(Instr. 3 and 4) 44,322		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code	action (Instr.	Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		piration ate	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Employee Stock Option (right to	\$0.6844	01/25/2012		A		285,000		(1)	01	/24/2022	Common Stock	285,000	\$0	285,00	00	D	

## **Explanation of Responses:**

 $1.\ This\ option\ vests\ with\ respect\ to\ 71,250\ shares\ on\ each\ of\ January\ 25,\ 2013,\ January\ 25,\ 2014,\ January\ 25,\ 2015\ and\ January\ 25,\ 2016.$ 

/s/ Phillip B. Donenberg

01/26/2012

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.